Even effective drugs require adequately powered trials: Systemic bevacizumab in hereditary hemorrhagic telangiectasia

J Intern Med. 2023 Dec;294(6):684-686. doi: 10.1111/joim.13713. Epub 2023 Aug 22.

Author

Hanny Al-Samkari^{1

2}

Affiliations

¹ Division of Hematology, Massachusetts General Hospital, Boston, Massachusetts, USA.
² Harvard Medical School, Boston, Massachusetts, USA.

PMID: 37608622
PMCID: PMC10841238 (available on 2024-12-01)
DOI: 10.1111/joim.13713

No abstract available

Publication types

Editorial

Grants and funding